StockGlow

ELI LILLY & COMPANY (LLYCL.SN)

Discovers and manufactures prescription medicines for diabetes, cancer, and immune system diseases.

1,129,700.00+0.06%Healthcare
Compare LLYCL.SN with
StockGlow Score
97
Bullish
BearishBullish
1 year ago+50.4%

The outlook

Eli Lilly stock is trading near its 52-week high, well above both its 50- and 200-day moving averages, signaling upward momentum in the recent trend. The trailing P/E of 42.6 reflects a premium valuation. Current market data shows strong technical positioning, though analyst coverage details aren't provided here.

What’s behind the score

Price trendAbove its 50- & 200-day averages
52-week range99% of the way from its 52-week low to high
Market cap
$1007.40T
52-wk high
1,134,700.00
52-wk low
608,400.00
50-day avg
1,043,674.50
200-day avg
934,846.60
Trailing P/E
42.6

Similar stocks

NVDACL.SNNVIDIA CORP.$185,390.00-7.03%TSLACL.SNTESLA INC.$291,720.00-0.78%METACL.SNMeta Platforms, Inc.$560,260.00-7.02%SAN.BABanco Santander, S.A.$88,950.00-0.59%LLY.BAEli Lilly and Company$34,880.00+2.11%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy